• Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
    • Årsredovisningar
      • 20/21
      • 21/22
      • 22/23
Hamlet BioPharmaHamlet BioPharma
  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
    • Series of digital events
    • Commercial collaborations
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Our Pipeline
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
    • Prospectus 2024
Press enter to begin your search
Category

Press releases

Mar 12 2025
Love0

Hamlet BioPharma bjuder in till investerarmöte den 12 mars

By Hamlet Biopharma Press releases

Som tidigare meddelats bjuder Hamlet BioPharma in till månatligt investerarmöte onsdagen den 12 mars, 2025, klockan 12.00. Klicka på länken nedan för a7 delta på…

Read More
Mar 11 2025
Love0

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB (publ) den 11 mars 2025

By Hamlet Biopharma Press releases

Vid extra bolagsstämma i Hamlet BioPharma AB (publ), org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) idag den 11 mars 2025 fattades bland annat följande beslut. Samtliga…

Read More
Feb 21 2025
Love0

Hamlet BioPharma bjuder in till investerarmöte den 21 februari

By Hamlet Biopharma Press releases

Med anledning av  Pressmeddelanden och nyheter bjuder Hamlet BioPharma in till investerarmöte fredagen den 21 februari, 2025, klockan 12.00. Bolaget kommer att  beskriva utvecklingen av…

Read More
Feb 20 2025
Love0

Kallelse till extra bolagsstämma i Hamlet BioPharma AB (publ)

By Hamlet Biopharma Press releases

Aktieägarna i Hamlet BioPharma AB (publ) (”Hamlet BioPharma” eller ”Bolaget”), org.nr 556568-8958, kallas härmed till extra bolagsstämma tisdagen den 11 mars 2025 kl. 11:00 i…

Read More
Feb 20 2025
Love0

The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value ​​for both companies

By Hamlet Biopharma Press releases

Hamlet BioPharma AB (“Hamlet BioPharma” or the “Company”), an innovative pharmaceutical company that develops new therapies against cancer and infections, announces that the Company’s board…

Read More
Feb 19 2025
Love0

Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd

By Hamlet Biopharma Press releases

Hamlet BioPharma has appointed Elisabeth Parker, PhD to strengthen the business development expertise in the company. Dr. Parker has 25 years’ experience of R&D, partnering…

Read More
Feb 18 2025
Love0

Catharina Svanborg appointed as CEO and assumes the position immediately, board member Magnus Nylén acting Chairman

By Hamlet Biopharma Press releases

The Board of Hamlet BioPharma has today decided to appoint Catharina Svanborg as CEO. Catharina immediately assumes the CEO role and continues as a Board…

Read More
Feb 13 2025
Love0

Q2 Interim Report October 2024 – December 2024

By Hamlet Biopharma Financial, Press releases

   

Read More
Feb 12 2025
Love0

Hamlet BioPharma bjuder in till pressträff den 13 februari med anledning av Q2 rapport

By Hamlet Biopharma Press releases

Med anledning av bolagets kvartalsrapport 2 för 2024/2025, bjuder Hamlet BioPharma in till en livesänd digital pressträff torsdagen den 13 februari, 2024, klockan 12.00. Bolaget…

Read More
Feb 03 2025
Love0

Presentation den 6.2.25 på Vetenskapsrådets konferens kring Antibiotikaresistens

By Hamlet Biopharma Press releases

Hamlet BioPharma AB, det innovativa läkemedelsbolaget, som utvecklar nya terapier mot cancer och infektioner, meddelar två viktiga händelser. Den 6 februari 2025 kommer Catharina Svanborg,…

Read More
Previous 1 2 3 4 … 9 Next

Related documents

  • PR Hamlet BioPharma 2025-0203.VR

See all news →

Recent Posts

  • Q3 Interim Report January – March 2025 May 22, 2025
  • Hamlet BioPharma bjuder in till pressträff den 22 maj May 21, 2025
  • Vetenskapligt genombrott för Alpha1H:s verkningsmekanism i blåscancer May 19, 2025
  • Scientific Breakthrough in Alpha1H’s Mechanism of Action May 19, 2025
  • Hamlet BioPharma presenterar framgångsrika prekliniska och kliniska data för Alpha1H vid AACR 2025 – stärker positionen inom behandling av blåscancer May 2, 2025

hbp-logo

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet Biopharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive newsletters

© 2025 Hamlet BioPharma.

  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
    • Series of digital events
    • Commercial collaborations
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Our Pipeline
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
    • Prospectus 2024
  • Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
    • Årsredovisningar
      • 20/21
      • 21/22
      • 22/23

Hamlet Pharma AB

BMC D10
Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00
info@hamletpharma.com

Swedish